23
total announcements
VINRKLB.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 16 Oct 2026
Market Cap
₹67 Cr
EPS (TTM)
₹-0.57
52W Low
₹4.50
52W High
₹65.07
Dividend Yield
0.00%
Beta
0.63
Price / Book
-29.5
Revenue (TTM)
₹2 Cr
Gross Margin
4.98%
Operating Margin
-18.02%
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has provided a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, confirming the dematerialization of securities for the quarter ended September 2026.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has appointed Mr. Subrata Samanta as its Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) with effect from 07.10.2026. Mr. Samanta has over 20 years of experience in finance and costing, and has worked with various multinational and Indian organizations.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has announced the voting results of its AGM, with all four resolutions passed. The resolutions include the adoption of audited financial statements, the appointment of a director, and the appointment of two independent directors.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd held its 38th Annual General Meeting (AGM) on September 29, 2026, through video conferencing. The meeting approved the audited financial statements for FY 2025-26 and appointed two independent directors, Mr. Prateek Jain and Mr. Jay Chintan Patel.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half year ended September 30, 2026.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has announced the resignation of Mr. Amit Shah as Managing Director, effective September 11, 2026, citing personal reasons and personal commitments. The company has also updated its registered office address.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has informed about a change in its registered office address, effective September 23, 2026, and the resignation of Mr. Amit Shah as Managing Director, effective September 11, 2026.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd announced the resignation of Mr. Amit Shah from the position of Managing Director and Director due to personal reasons, effective September 11, 2026.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has announced its Annual Report FY2526, including notice of AGM, audited financial statements, and director appointments.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has announced that its 38th Annual General Meeting will be held on September 29, 2026, through online mode. The meeting will consider and adopt the audited financial statement for the financial year 2025-26, re-appoint Mrs. Ilaben Pathak as a director, and appoint Mr. Prateek Jain and Mr. Jay Chintan Patel as independent directors.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd announced the resignation of Mr. Deepak Khandelwal as Company Secretary and Compliance Officer due to personal reasons, effective September 2, 2026.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating a potential change in control or significant stake acquisition by Surbhit Mukesh Shah and others.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, related to a substantial acquisition of shares by Dhruvalkumar Patel.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd clarifies that it is not aware of any undisclosed price-sensitive information or material event that may have a bearing on the price movement of its securities.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has announced its Q1 FY2026-27 financial results, with revenue from operations at Rs. 6 lacs, total income at Rs. 6.85 lacs, and a net loss of Rs. 12.05 lacs. The company has also appointed Mr. Surbhit Shah as the Chairman of the Board of Directors.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has announced its standalone unaudited financial results for the quarter ended 30th June 2026, with revenue from operations at Rs. 6 lacs, total income at Rs. 6.85 lacs, and a net loss of Rs. 12.05 lacs. The company has also appointed Mr. Surbhit Shah as the Chairman of the Board of Directors.
Rekvina Laboratories Ltd
The BSE has sought clarification from Rekvina Laboratories Ltd regarding significant price movement to ensure investors have relevant information.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has approved the allotment of 50,87,750 equity shares to promoters and non-promoters on a preferential basis, with Radiant Parenterals Limited becoming a wholly-owned subsidiary post-acquisition.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has scheduled a board meeting on 13th August, 2026 to consider and approve unaudited financial results for the quarter ended 30th June, 2026.
Rekvina Laboratories Ltd
Rekvina Laboratories Ltd has received a post-offer advertisement for the acquisition of up to 28,90,100 equity shares by Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel, representing 26% of the expanded share capital. The offer was made pursuant to the Securities and Exchange Board of India (Substantial Acquisitions of Shares and Takeovers) Regulations, 2011.